Does Rallies summarize LEXX news?

Yes. Rallies summarizes LEXX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.

Is LEXX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LEXX. It does not provide personalized investment advice.

LEXX (Lexaria Bioscience Corp. Common Stock) Stock Analysis - News

Lexaria Bioscience Corp. Common Stock (LEXX) is a publicly traded Healthcare sector company. As of May 19, 2026, LEXX trades at $0.57 with a market cap of $14.68M and a P/E ratio of 0.00. LEXX moved -0.07% today. Year to date, LEXX is -14.36%; over the trailing twelve months it is -44.54%. Its 52-week range spans $0.46 to $3.39. Rallies surfaces LEXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in LEXX news today?

Lexaria Bioscience Secures IRB Approval for Five-Week DHT-Semaglutide Study Against Wegovy: Lexaria Bioscience received IRB approval to initiate a five-week Human Pilot Study #7 evaluating two oral DehydraTECH-semaglutide formulations against Wegovy tablets, featuring tablet and capsule SNAC-inclusive compositions. Third-party QC testing of test articles completes in early June ahead of mid-June dosing.

LEXX Key Metrics

Key financial metrics for LEXX
Metric	Value
Price	$0.57
Market Cap	$14.68M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$3.39
52-Week Low	$0.46
Volume	38.50K
Avg Volume	0
Revenue (TTM)	$705.92K
Net Income	$-11.91M
Gross Margin	99.61%

Latest LEXX News

Lexaria Bioscience Secures IRB Approval for Five-Week DHT-Semaglutide Study Against Wegovy — May 19, 2026
Lexaria Extends Material Transfer Agreement Through 2026, Highlights GLP-1 Research — May 7, 2026
Lexaria Completes Manufacturing for Oral DHT-Semaglutide Study, Ethics Approval Submitted — May 5, 2026
Lexaria Launches 18-Arm GLP-1 Animal Study Testing Amycretin and Retatrutide — Apr 23, 2026
Lexaria Eyes Up to $60B Oral GLP-1 Pill Market with DehydraTECH — Apr 21, 2026

Recent LEXX Insider Trades

BUNKA CHRISTOPHER bought 11.90K (~$10.87K) on Jul 30, 2025.
BUNKA CHRISTOPHER bought 15.60K (~$14.38K) on Jul 29, 2025.
McKechnie William Edward bought 5.00K (~$4.53K) on Jul 29, 2025.

LEXX Analyst Consensus

LEXX analyst coverage data. Average price target: $0.00.

Common questions about LEXX

What changed in LEXX news today?: Lexaria Bioscience Secures IRB Approval for Five-Week DHT-Semaglutide Study Against Wegovy: Lexaria Bioscience received IRB approval to initiate a five-week Human Pilot Study #7 evaluating two oral DehydraTECH-semaglutide formulations against Wegovy tablets, featuring tablet and capsule SNAC-inclusive compositions. Third-party QC testing of test articles completes in early June ahead of mid-June dosing.
Does Rallies summarize LEXX news?: Yes. Rallies summarizes LEXX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is LEXX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LEXX. It does not provide personalized investment advice.